SMAD2 and prostate carcinoma: Another relevant inquiry buttressed that upregulation of miR-19a-3p represses migration, invasion, and bone metastasis of prostate cancer cells by attenuating the expression of SMAD2 and SMAD4 (responsible for activating the TGF-β signaling pathway), associated with bone metastasis in prostate cancer [110].